title: [Intraocular bevacizumab as palliative therapy in melanoma-metastasis-associated rubeotic secondary glaucoma].
authors.affiliation: Universitäts-Augenklinik, Department für Augenheilkunde,Eberhard-Karls-Universität Tübingen, Tübingen. gesine.jaissle@googlemail.com
authors.forename: G B
authors.initials: GB
authors.lastname: Jaissle
authors.forename: A
authors.initials: A
authors.lastname: Ulmer
authors.forename: S
authors.initials: S
authors.lastname: Henke-Fahle
authors.forename: S
authors.initials: S
authors.lastname: Aisenbrey
authors.forename: G
authors.initials: G
authors.lastname: Fierlbeck
authors.forename: K U
authors.initials: KU
authors.lastname: Bartz-Schmidt
authors.forename: P
authors.initials: P
authors.lastname: Szurman
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005134:Eye Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D005901:Glaucoma / Q000188:drug therapy* / Q000209:etiology*; D006801:Humans; D015552:Injections, Intralesional; D008297:Male; D008545:Melanoma / Q000150:complications / Q000188:drug therapy* / Q000556:secondary*; D010166:Palliative Care / Q000379:methods; D012878:Skin Neoplasms / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab